Baijin Life Science Holdings Limited
MNNGF
$0.08
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.39M | 15.06M | 12.73M | 9.79M | 6.86M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.39M | 15.06M | 12.73M | 9.79M | 6.86M |
| Cost of Revenue | 12.00M | 10.62M | 9.24M | 6.89M | 4.55M |
| Gross Profit | 5.39M | 4.44M | 3.49M | 2.90M | 2.31M |
| SG&A Expenses | 4.59M | 4.65M | 4.72M | 4.16M | 3.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.58M | -834.60K | -89.00K | 104.20K | 296.90K |
| Total Operating Expenses | 15.01M | 14.44M | 13.87M | 11.15M | 8.44M |
| Operating Income | 2.38M | 622.50K | -1.14M | -1.36M | -1.58M |
| Income Before Tax | -175.80K | -439.80K | -704.00K | -897.40K | -1.09M |
| Income Tax Expenses | -165.80K | 84.90K | 335.80K | 168.70K | 2.00K |
| Earnings from Continuing Operations | -0.01 | -0.52 | -1.04 | -1.07 | -1.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -27.20K | -220.40K | -413.70K | -136.40K | 140.30K |
| Net Income | -37.40K | -745.30K | -1.45M | -1.20M | -952.20K |
| EBIT | 2.38M | 622.50K | -1.14M | -1.36M | -1.58M |
| EBITDA | 2.85M | 1.00M | -844.70K | -1.17M | -1.50M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 2.78B | 2.72B | 2.66B | 2.62B | 2.58B |
| Average Diluted Shares Outstanding | 2.78B | 2.72B | 2.66B | 2.62B | 2.58B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |